Neogen Co. (NASDAQ:NEOG - Get Free Report) COO Douglas Edward Jones acquired 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 17th. The shares were purchased at an average price of $12.36 per share, with a total value of $123,600.00. Following the acquisition, the chief operating officer now owns 46,131 shares of the company's stock, valued at approximately $570,179.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Neogen Stock Down 0.2 %
Shares of Neogen stock traded down $0.02 on Wednesday, hitting $12.14. The company had a trading volume of 3,141,069 shares, compared to its average volume of 2,125,894. The stock has a 50-day moving average of $15.68 and a 200-day moving average of $16.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.82 and a quick ratio of 2.66. The firm has a market capitalization of $2.63 billion, a P/E ratio of 1,227.00 and a beta of 1.13. Neogen Co. has a twelve month low of $11.74 and a twelve month high of $24.09.
Neogen (NASDAQ:NEOG - Get Free Report) last announced its quarterly earnings data on Tuesday, April 9th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.14 by ($0.02). The business had revenue of $228.80 million during the quarter, compared to the consensus estimate of $230.01 million. Neogen had a return on equity of 3.35% and a net margin of 0.17%. The business's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.12 EPS. Research analysts predict that Neogen Co. will post 0.5 earnings per share for the current year.
Institutional Trading of Neogen
A number of institutional investors have recently made changes to their positions in NEOG. Fairfield Bush & CO. raised its position in Neogen by 3.5% during the first quarter. Fairfield Bush & CO. now owns 75,222 shares of the company's stock worth $2,320,000 after acquiring an additional 2,572 shares in the last quarter. Raymond James & Associates raised its position in Neogen by 3.3% during the first quarter. Raymond James & Associates now owns 124,917 shares of the company's stock worth $3,852,000 after acquiring an additional 3,974 shares in the last quarter. HighTower Advisors LLC raised its position in Neogen by 3.6% during the first quarter. HighTower Advisors LLC now owns 44,465 shares of the company's stock worth $1,373,000 after acquiring an additional 1,540 shares in the last quarter. Panagora Asset Management Inc. raised its position in Neogen by 29.3% during the first quarter. Panagora Asset Management Inc. now owns 20,573 shares of the company's stock worth $634,000 after acquiring an additional 4,661 shares in the last quarter. Finally, Rhumbline Advisers raised its position in Neogen by 2.3% during the first quarter. Rhumbline Advisers now owns 305,783 shares of the company's stock worth $9,430,000 after acquiring an additional 6,931 shares in the last quarter. Institutional investors own 96.73% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, Piper Sandler reduced their price target on shares of Neogen from $19.00 to $17.00 and set a "neutral" rating for the company in a report on Monday.
Get Our Latest Report on NEOG
Neogen Company Profile
(
Get Free Report)
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.
See Also
Before you consider Neogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neogen wasn't on the list.
While Neogen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
